We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Malin Corporation Plc | LSE:0Y71 | London | Ordinary Share | IE00BVGC3741 | MALIN CORPORATION ORD SHS |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.00 | - |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Offices-holdng Companies,nec | 0 | 0 | 0.0000 | N/A | 102.95M |
From May 2019 to May 2024
TIDM0Y71
RNS Number : 7160V
Malin Corporation PLC
11 August 2020
Malin Corporation plc
Notice of 2020 Interim Results
Dublin-Ireland, 11 August 2020 : Malin Corporation plc. (Euronext Growth Dublin:MLC) ("Malin"), a company investing in highly innovative life sciences companies, will announce its interim financial results and publish its interim report for the six month period ending 30 June 2020 at 07:00am Irish Standard Time / BST on Wednesday, 2 September 2020.
Darragh Lyons, Chief Executive Officer, will host a conference call for analysts and investors at 12:00pm Irish Standard Time / BST on the day of publication. This call can be accessed as follows:
From Ireland dial: +353 ( 0) 1 431 9615 From the UK dial: +44 (0) 844 571 8892 From the USA dial: +(1) 6315 107 495 From other locations dial: +44 (0) 2071 928 000 Participant PIN code: 5570129
The Company's interim results press release and presentation will be available on the website at 07:00am Irish Standard Time / BST on 2 September 2020 at www.malinplc.com .
ENDS
About Malin Corporation plc
Malin (Euronext Growth Dublin:MLC) is a company investing in highly innovative life sciences companies. Its purpose is to create shareholder value through the application of long-term capital and operational and strategic expertise to a diverse range of global healthcare businesses. Malin has a focus on innovative businesses underpinned by exceptional science and works with its investee companies, providing strategic and financial support to enable them to reach their value potential. Malin is headquartered and domiciled in Ireland and listed on the Euronext Growth Dublin. For more information visit www.malinplc.com
For further information contact:
Malin
Jessica Bergin, Investor Relations & External Reporting
Tel: +353 (0)1 901 5700
investorrelations@malinplc.com
Davy Corporate Finance (Euronext Growth Adviser & Joint Broker)
Brian Garrahy / Daragh O'Reilly
Tel: +353 1 679 6363
Liberum (Joint Broker)
Bidhi Bhoma / Euan Brown
Tel: +44 (0) 20 3100 2000
Consilium Strategic Communications
Mary-Jane Elliott / Chris Welsh
Tel: +44 (0)20 3709 5700
malin@consilium-comms.com
Powerscourt (Irish media enquiries)
Eavan Gannon
Tel: +353 87 236 5973
malin@powerscourt-group.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
NORLBLLFBVLFBBB
(END) Dow Jones Newswires
August 11, 2020 02:00 ET (06:00 GMT)
1 Year Malin Chart |
1 Month Malin Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
